Results 51 to 60 of about 3,056 (181)

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

, 2022
IMPORTANCE: Plasma biomarkers of Alzheimer disease may be useful as minimally invasive pharmacodynamic measures of treatment outcomes. OBJECTIVE: To analyze the association of donanemab treatment with plasma biomarkers associated with Alzheimer disease ...
Sims, John R., Collins, Emily C., Pontecorvo, Michael J., Schade, Andrew E., Shcherbinin, Sergey, Lu, Ming, Dage, Jeffrey L., Mintun, Mark A., Burnham, Samantha C.   +8 more
core   +1 more source

Research Trends and Mechanistic Insights Into Natural Medicines for Alzheimer's Disease: A Bibliometric Analysis and Narrative Review

Phytotherapy Research, EarlyView.
Research landscape and mechanistic insights into natural medicines for Alzheimer's disease. ABSTRACT Natural medicines have been widely investigated for Alzheimer's disease (AD), but the development of this field and the relationship between bibliometric themes and experimental evidence remain insufficiently characterized.
Maoning Wang, Xiaolian Zhang, Huaxian Yang, Jianhe Zhao, Wentao Wei, Qian Zhao, Wenjia Wang, Yunhui Hu, Jiansong Fang   +8 more
wiley   +1 more source

Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit [PDF]

Based on “reducing amyloid plaques in the brain”, the U.S. Food and Drug Administration has granted accelerated and full approval for two monoclonal anti-Alzheimer's antibodies, aducanumab and lecanemab, respectively.
Herrup, Karl, Alavi, Abass, Vissel, Bryce, Perry, George, Neve, Rachael L., Revheim, Mona Elisabeth, Kepp, Kasper P., Barrio, Jorge R., Høilund-Carlsen, Poul F., Costa, Tommaso, Sensi, Stefano L., Castellani, Rudolph J., Robakis, Nikolaos K.   +12 more
core   +1 more source

The Crosstalk Between Diabetes and Alzheimer's Disease: A Molecular Perspective

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 4, October 2026.
Increasing evidence indicates an association between type 2 diabetes mellitus and Alzheimer’s disease, contributing to the proposed concept of AD as “type 3 diabetes.” Shared biological features such as impaired insulin signaling, chronic inflammation, mitochondrial dysfunction, and oxidative stress have been observed in both T2DM and AD.
Deniz Catakli, Ozlem Ozen‐Basoglu, Ebru Busra Tuncgovde, Gonen Ozsarlak‐Sozer   +3 more
wiley   +1 more source

Donanemab in Japanese Patients with Early Alzheimer’s Disease: Subpopulation Analysis of the TRAILBLAZER-ALZ 2 Randomized Trial

Neurology and Therapy
Introduction Donanemab, a monoclonal antibody directed against an insoluble, modified, N-terminal truncated form of amyloid beta, demonstrated efficacy and safety in patients with early, symptomatic Alzheimer’s disease (AD) in the phase 3 TRAILBLAZER-ALZ
Shoichiro Sato, Naohisa Hatakeyama, Shinji Fujikoshi, Sadao Katayama, Hideaki Katagiri, John R. Sims   +5 more
doaj   +1 more source

Mitochondria‐Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential

Advanced Healthcare Materials, Volume 15, Issue 36, 25 September 2026.
Mitochondria‐targeted nanotherapies emerge as a promising strategy for combating aging‐associated neurodegenerative disorders (NDs) by restoring mitochondrial function, reducing oxidative stress, and improving neuronal survival. Recent advances in nanotechnology, therapeutic delivery, and translational research are highlighted, providing insights into ...
Dnyandev G. Gadhave, Ashish B. Jadhav, Nitin B. Waghamode, Shubham Khot, Rajiya Khan, Ravi Hole, Shankar M. Dhobale, Manoj Aswar, Keshav Raj Paudel   +8 more
wiley   +1 more source

Eficacia del lecanamab versus donanemab en el tratamiento de la enfermedad de Alzheimer: revisión sistemática [PDF]

Antecedentes: El Alzheimer es una neuropatología de tipo progresiva, afecta la memoria y la capacidad de razonamiento. Este padecimiento es considerado el tipo de demencia más común y entre los fármacos a estudiar tenemos lecanemab y donanemab. Objetivo:
Vera Siguenza, Juan Sebastián
core   +1 more source

More efficient screening for preclinical Alzheimer's clinical trials using mixture of experts

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION Blood plasma biomarkers identifying Alzheimer's disease (AD) neuropathology offer accessible and scalable alternatives to lumbar puncture and positron emission tomography (PET) scans, with potential efficiency gains in clinical trial recruitment.
Oliver Langford, Rema Raman, Paul Aisen, Reisa Sperling, Keith Johnson, Doris Molina‐Henry, Pallavi Sachdev, David Li, Gustavo A. Jimenez‐Maggiora, Sterling C. Johnson, Joel B Braunstein, Colin Birkenbihl, Madison Cuppels, Rachel F. Buckley, Robert A. Rissman, Michael C. Donohue   +15 more
wiley   +1 more source

Safety Concerns in Neurological Clinical Trials: A Challenge That the FDA Must Resolve

Biomedicines
Background: Monoclonal antibodies approved by the FDA, lecanemab, donanemab, and aducanumab, are failing to meet the expected efficacy to treat early Alzheimer’s disease, and aducanumab has been recalled.
Sarfaraz K. Niazi
doaj   +1 more source

Outcomes reported in interventional studies for mild cognitive impairment: a scoping umbrella review to inform core outcome set development

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract There is currently no consensus on the most important treatment outcomes in patients with mild cognitive impairment (MCI). As part of developing a core outcome set for MCI, we conducted a pragmatic scoping umbrella review to summarize outcomes reported in previous studies.
Victoria Grace Gabb, Sam Harding, Tomas Lemke, Sophie Alderman, Natalie Woodward, Julie Clayton, Angus McNair, Winsome Barrett‐Muir, Alan Richardson, Jemima Dooley, Sarah Rudd, Elizabeth Coulthard, Nicholas Turner   +12 more
wiley   +1 more source